Is pregabalin safe for use in a lactating mother?

Pregabalin Safety During Breastfeeding

Breastfeeding is not recommended during treatment with pregabalin due to potential tumorigenicity risk to the infant, according to the FDA drug label. 1

FDA Official Recommendation

The FDA explicitly states that "breastfeeding is not recommended during treatment with pregabalin" based on animal studies showing potential tumorigenicity risk with pregabalin exposure via breast milk. 1 This is the highest-level regulatory guidance available and should take precedence in clinical decision-making.

Pharmacokinetic Data in Lactating Women

• Pregabalin transfers into breast milk at substantial concentrations: A pharmacokinetic study in 10 lactating women (≥12 weeks postpartum) found pregabalin in breast milk at average steady-state concentrations approximately 76% of maternal plasma levels. 1, 2

• The estimated infant dose is approximately 7% of the weight-adjusted maternal dose (0.31 mg/kg/day), assuming mean milk consumption of 150 mL/kg/day. 1, 3, 2

• This 7% relative infant dose (RID) is below the theoretical 10% safety threshold commonly cited in lactation guidelines, but the FDA recommendation remains against breastfeeding due to tumorigenicity concerns from animal data. 3, 2

Critical Safety Concerns

• Animal studies demonstrate tumorigenicity risk: Pregabalin caused tumors in rodent studies, and exposure via breast milk poses a theoretical risk to the breastfed infant. 1

• Human data on tumorigenicity are inconclusive: Available clinical data in patients >12 years of age do not provide clear conclusions about tumorigenicity risk in humans. 1

• No data exist on pregabalin's effects on milk production or on breastfed infants: The pharmacokinetic study did not evaluate these outcomes because infants did not receive milk obtained during the dosing period. 1, 2

Clinical Context and Alternative Considerations

• Some sources suggest pregabalin may be compatible with breastfeeding based solely on the low RID and pharmacokinetic profile, but these recommendations do not adequately address the FDA's tumorigenicity warning. 4, 5

• The FDA warning is based on animal data, not human outcomes: No documented cases of tumors in breastfed infants have been reported in the literature, but the theoretical risk remains. 1

Common Pitfalls to Avoid

• Do not rely solely on the 7% RID calculation to determine safety—the FDA's tumorigenicity concern supersedes this threshold. 1

• Do not confuse pregabalin with gabapentin or other medications that may have different lactation safety profiles. 4

• Avoid prescribing pregabalin to lactating mothers without explicitly discussing the FDA recommendation to discontinue breastfeeding during treatment. 1

Practical Clinical Algorithm

1. If pregabalin is being considered for a lactating mother:

   • Inform her that the FDA recommends against breastfeeding during treatment. 1
   • Discuss alternative medications with established lactation safety (e.g., gabapentin for neuropathic pain, SSRIs for anxiety). 4, 5

2. If pregabalin is medically necessary and no alternatives exist:

   • Advise the mother to discontinue breastfeeding for the duration of treatment. 1
   • Counsel on formula feeding and lactation suppression if needed.

3. If the mother chooses to continue breastfeeding despite the FDA warning:

   • Document informed consent and shared decision-making.
   • Monitor the infant closely for any adverse effects (though specific monitoring parameters are not established). 1